- 1 TITLE: Early outcomes of tocilizumab in adults hospitalized with severe COVID-19 –
- 2 SUBTITLE: An initial report from the Vall d'Hebron COVID-19 prospective cohort
- 3 study.

11

16

21

26

31

36

- 5 Adrián Sánchez-Montalvá, Júlia Sellarés-Nadal, Juan Espinosa-Pereiro, Nuria
- 6 Fernández-Hidalgo, Santiago Pérez-Hoyos, Fernando Salvador, Xavier Durà, Marta
- 7 Miarons, Andrés Antón, Simeón Eremiev-Eremiev, Abiu Sempere-González, Arnau
- 8 Monforte-Pallarés, Pau Bosch-Nicolau, Salvador Augustin, Júlia Sampol, Alfredo
- 9 Guillén-del-Castillo, Benito Almirante on behalf of the Vall d'Hebron COVID-19
- 10 working group.
- 12 Adrián Sánchez-Montalvá
- 13 Infectious Diseases Department, Tropical Diseases and Global Health Unit, Vall d'Hebron
- 14 University Hospital, 08035, Barcelona, Spain
- 15 Consulting physician
- 17 Júlia Sellarés-Nadal
- 18 Internal Medicine and Infectious Diseases Department, Vall d'Hebron University Hospital,
- 19 08035, Barcelona, Spain
- 20 Resident
- 22 Juan Espinosa-Pereiro
- 23 Infectious Diseases Department, Tropical Diseases and Global Health Unit, Vall d'Hebron
- 24 University Hospital, 08035, Barcelona, Spain
- 25 Assistant physician
- 27 Nuria Fernández-Hidalgo
- 28 Infectious Diseases Department, Cardiovascular Infections Unit, Vall d'Hebron University
- 29 Hospital, 08035, Barcelona, Spain
- 30 Consulting physician
- 32 Santiago Pérez-Hoyos
- 33 Statistics and Bioinformatics Unit, Vall d'Hebron Research Institute, 08035, Barcelona,
- 34 Spain
- 35 Statistician

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

37 Fernando Salvador

- 38 Infectious Diseases Department, Tropical Diseases and Global Health Unit, Vall d'Hebron
- 39 University Hospital, 08035, Barcelona, Spain
- 40 Consulting physician
- 42 Xavier Durà
- 43 Internal Medicine and Infectious Diseases Department, Vall d'Hebron University Hospital,
- 44 08035, Barcelona, Spain
- 45 Resident

41

46

50

54

59

64

69

74 75

79

- 47 Marta Miarons
- 48 Hospital Pharmacy, Vall d'Hebron University Hospital, 08035, Barcelona, Spain
- 49 Pharmacist
- 51 Andrés Antón
- 52 Microbiology Department, Vall d'Hebron University Hospital, 08035, Barcelona, Spain
- 53 Microbiologist.
- 55 Simeón Eremiev-Eremiev,
- 56 Internal Medicine and Infectious Diseases Department, Vall d'Hebron University Hospital,
- 57 08035, Barcelona, Spain
- 58 Resident
- 60 Abiu Sempere-González,
- 61 Internal Medicine and Infectious Diseases Department, Vall d'Hebron University Hospital,
- 62 08035, Barcelona, Spain
- 63 Resident
- 65 Arnau Monforte-Pallarés.
- 66 Internal Medicine and Infectious Diseases Department, Vall d'Hebron University Hospital,
- 67 08035, Barcelona, Spain
- 68 Resident
- 70 Pau Bosch-Nicolau,
- 71 Infectious Diseases Department, Tropical Diseases and Global Health Unit, Vall d'Hebron
- 72 University Hospital, 08035, Barcelona, Spain
- 73 Assistant physician
 - Salvador Augustin,
- 76 Internal Medicine and Hepatology, Vall d'Hebron University Hospital, 08035, Barcelona,
- 77 Spain
- 78 Consulting physician
- 80 Júlia Sampol,
- Pneumology, Vall d'Hebron University Hospital, 08035, Barcelona, Spain
- 82 Assistant physician

Alfredo Guillén-del-Castillo,

- 85 Internal Medicine, Systemic Diseases Unit, Vall d'Hebron University Hospital, 08035,
- 86 Barcelona, Spain
- 87 Consulting physician

89 Benito Almirante

- 90 Infectious Diseases Department, Vall d'Hebron University Hospital, 08035, Barcelona,
- 91 Spain

84

88

93

94

101

121

122

92 Head of department, associate professor

Address correspondence to:

- 95 Adrián Sánchez-Montalvá, MD, PhD
- 96 ORCID: 0000-0002-2194-5447
- 97 Address: Passeig Vall d'Hebron, 119-129. Hospital Universitario Vall d'Hebron. Edificio
- 98 General. Enfermedades Infecciosas. 6^a planta. CP 08035. Barcelona. Spain.
- e-mail: adsanche@vhebron.net . Telephone number: +34 93 274 6090 Fax number: +34 93
- 100 489 40 91.

102 Contributions:

- Adrián Sánchez-Montalvá: conceptualization, database design, data curation, statistical
- analysis, first draft writing
- 105 Júlia Sellarés-Nadal: data collection, draft review
- 106 Juan Espinosa-Pereiro: database design, data curation, draft review
- Nuria Fernández-Hidalgo: conceptualization, statistical analysis, draft review
- 108 Santiago Pérez-Hoyos: data curation, statistical analysis
- 109 Fernando Salvador: draft review
- 110 Xavier Durà: data collection, draft review
- 111 Marta Miarons: data collection, draft review
- Andrés Antón: microbiological methods, data collection, draft review
- 113 Simeón Eremiev-Eremiev: data collection, draft review
- 114 Abiu Sempere-González: data collection, draft review
- 115 Arnau Monforte-Pallarés: data collection, draft review
- Pau Bosch-Nicolau: data collection, draft review
- 117 Salvador Augustin: data collection, draft review
- 118 Júlia Sampol: data collection, draft review
- 119 Alfredo Guillén-del-Castillo: data collection, draft review
- 120 Benito Almirante: guarantor, draft review

License for publication:

- 123 The Corresponding Author has the right to grant on behalf of all authors and does grant on
- behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity,
- in all forms, formats and media (whether known now or created in the future), to i) publish,
- reproduce, distribute, display and store the Contribution, ii) translate the Contribution into
- other languages, create adaptations, reprints, include within collections and create
- summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative

work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

Conflicts of interest

All authors have completed the ICMIE uniform disclosure form and declare; no support

All authors have completed the ICMJE uniform disclosure form and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

ABSTRACT Background: Modulation of the immune system to prevent lung injury is being widely used against the new coronavirus disease (COVID-19) despite the scarcity of evidence. Methods: We report preliminary results from the Vall d'Hebron prospective cohort study at Vall d'Hebron University Hospital, in Barcelona (Spain), including all consecutive patients who had a confirmed infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and who were treated with tocilizumab until March 25th. The primary endpoint was mortality at 7 days after tocilizumab administration. Secondary endpoints were admission to the intensive care unit, development of ARDS and respiratory insufficiency among others. **Results:** 82 patients with COVID-19 received at least one dose of tocilizumab. The mean (± SD) age was 59.1 (19.8) years, 63% were male, 22% were of non-Spanish ancestry, and the median (IQR) age-adjusted Charlson index at baseline was 3 (1-4) points. Respiratory failure and ARDS developed in 62 (75.6%) and 45 (54.9%) patients, respectively. Median time from symptom onset to ARDS development was 8 (5-11) days. The median time from symptom onset to the first dose of tocilizumab was 9 (7-11) days. Mortality at 7 days was 26.8%. Hazard ratio for mortality was 3.3; 95% CI, 1.3 to 8.5 (age-adjusted hazard ratio for mortality 2.1; 95% CI, 0.8 to 5.8) if tocilizumab was administered after the onset of ARDS. Conclusion: Time from lung injury onset to tocilizumab administration may be critical to patient recovery. Our preliminary data could inform bedside decisions until more data from clinical trials becomes available.

INTRODUCTION:

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

Coronavirus disease 2019 (COVID-19) is a novel illness caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It was first reported in December 2019 in Hubei province, China. Since then, SARS-CoV-2 has rapidly spread worldwide. According to the World Health Organization (WHO), as of April 13th, 2020, there has been 1773084 laboratory-confirmed cases and 111652 deaths.² The case fatality rate, estimated between 2.3% and 3.3%, is highly age and underlying conditions dependent.^{3,4} Death is mainly due to respiratory failure caused by an acute respiratory distress syndrome (ARDS). As the physiopathology behind lung injury is progressively elucidated, several therapies have been proposed on the basis of pre-clinical studies and the previous experience with the severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV).^{5,6} Many of them are being used off label in a desperate attempt to improve patient outcomes, including antiviral therapies, coagulation modifying drugs and immune-modulating therapies. 7–11 In COVID-19, an excessive immune response inducing disproportionate release of cytokine and hyperinflammation has been proposed as cause for the lung damage mimicking a secondary haemophagocytic lymphohistiocytosis. 12 Host-directed therapies have immunemodulating properties with higher precision than steroids and other immune-modulating therapies. 13 Tocilizumab is a humanized monoclonal antibody that inhibits interleukin-6 (IL-6) receptor with a well-known safety profile approved for the treatment of rheumatoid arthritis and, since 2017, also approved for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS). 14,15 It has been used with promising results in small retrospective cohort studies of SARS-CoV-2 infected patients in China. 9,16 The efficacy of other host-directed therapies targeting

hyperinflammation is being assessed under randomized clinical trial conditions for severe SARS-CoV-2 infected patients.^{17,18}

However, a proper characterization of the subset of patients who will benefit most from host-directed therapies and defining the precise timing for host-directed therapies administration has not yet been performed and is critical to allocate limited drug stocks and reduce COVID-19 associated mortality. We aim to describe the characteristics of SARS-CoV-2 infected patients treated with tocilizumab and define poor outcome risk factors.

METHODS

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

Study setting and population The Vall d'Hebron COVID-19 Prospective Cohort Study includes all consecutive adult patients (≥ 18 years old) diagnosed with COVID-19 at Vall d'Hebron University Hospital, a 1100-beds public tertiary care hospital in Barcelona, Spain. For this study we selected the subgroup of patients with laboratory-confirmed COVID-19 and radiologically confirmed pneumonia who received at least one dose of tocilizumab. Identification and inclusion of patients receiving tocilizumab was assured from the Pharmacy Department registry. Standard of care and tocilizumab administration criteria At admission, all patients were initially evaluated with chest radiography and blood test including cell count, coagulation study, biochemistry and inflammatory parameters. Treatment with lopinavir/ritonavir, azithromycin and hydroxychloroquine was initiated according to Vall d'Hebron University Hospital protocol. Tocilizumab was considered as additional treatment in patients with the following criteria: 1) respiratory failure defined as a ratio of arterial oxygen tension to fraction of inspired oxygen (PaO2/FiO2 ratio) of <300, a ratio of arterial oxygen saturation measured by pulse oximetry to fraction of inspired oxygen (SpO2/FiO2 ratio) of <315 or pO2 <60mmHg or oxygen saturation measured by pulse oximetry less than 90% when breathing room air or rapidly progressive clinical worsening according to treating physician and 2) interleukin-6 (IL-6) levels >40pg/mL (reference 0-4.3pg/mL) or a D-dimer levels > 1500 ng/mL. Two weight bands were considered for tocilizumab dosing. Patients over 75kg received 600mg, otherwise 400mg was the preferred dose. A second dose was considered in patients with a poor early response. Patients with liver enzymes 5 times over the upper limit of normality or

concomitant severe bacterial infection were not eligible for tocilizumab treatment.

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

Data sources Data were collected retrospectively from the medical charts of the patients from the 13th of March, 2020 to the 18th of March, 2020, when the protocol was submitted to the institutional review board, and prospectively thereafter. Inclusion and follow-up are still ongoing. The cut-off data for inclusion in this sub-study was March 25th, 2020. All patients included were followed directly (admitted to medical or intensive care unit wards) for at least 7 days. Laboratory-confirmed case was defined as a patient with a real-time reverse-transcriptasepolymerase-chain-reaction (RT-PCR) SARS-CoV-2 positive result in any respiratory sample (nasopharyngeal swab, sputum, bronchoalveolar lavage or aspirate, tracheal aspirate). We collected sociodemographic characteristics, past medical history, Charlson comorbidity score, concomitant medication, current therapy, adverse drug events (graded according to the Common Terminology Criteria for Adverse Events, CTCAE, version 5), blood test results, imaging studies, microbiological tests other than SARS-CoV-2 RT-PCR on respiratory samples when available, and supportive measures needed. Vital signs, symptoms and physical examination were evaluated on admission, at 48h and weekly during hospital admission. Laboratory, microbiology and imaging studies were performed on admission and thereafter according to the clinical care needs of each patient. Laboratory assessments consisted of a complete blood count, coagulation testing including D-dimer measurement, liver and renal function, electrolyte profile, and inflammatory profile including C-reactive protein, fibrinogen, ferritin and IL-6. All radiographs were reviewed by the investigators and computed tomography (CT) scans were recorded according to the

radiology department reports. The severity of the COVID-19 was measured with the

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

CURB-65 scale for community acquired pneumonia and other scales. 19,20 Data was recorded in the Research Electronic Data Capture software (REDCap, Vanderbilt University). Laboratory confirmation From the onset of the outbreak until 15th of March the microbiological diagnosis was based on a homebrew RT-PCR assay targeting two viral targets (N1 and N2) into viral nucleocapsid (N) gene and one into envelope (E) gene of SARS-CoV-2, as well as the human RNase P (RP) gene as an internal control of the whole process, according to the CDC and ECDC Real-Time RT-PCR Diagnostic Panels with minor modifications.²¹ Since March 15th, commercial AllplexTM 2019-nCoV multiplex RT-PCR (Seegene, South Korea) were used for the detection of three viral targets (E; N; and, RNA-dependent RNA polymerase, RdRp) and an internal control. First SARS-CoV-2 laboratory-confirmations were confirmed by RdRp sequencing.^{22,23} Total nucleic acids (DNA/RNA) were extracted from respiratory specimens using NucliSENS easyMAG (BioMerieux, France) and STARMag Universal Cartridge Kit (Seegene, South Korea) according to the manufacturer's instructions. All microbiological procedures were carried out in the laboratory under Biosafety Level 2 conditions. **Study outcomes** The primary simple endpoint was defined as death at 7 days after first dose of tocilizumab. Secondary outcomes were admission to Intensive Care Unit (ICU), acute Respiratory Distress Syndrome (ARDS) and respiratory insufficiency progression. We also assessed acute myocardial infarction, septic shock, acute kidney injury and secondary infections. Berlin criteria for the ARDS were adapted, as many of the patients did not have an

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

available arterial O2 pressure due to the overwhelming volume of admitted patients that precluded us from performing arterial blood samples to all patients. Instead, we used oxygen saturation by pulse oximetry and its correlation to the inspired fraction of oxygen (SpO2/FiO2 ratio < 315). ^{24,25} One patient died a few hours after receiving tocilizumab and was excluded from the primary endpoint analysis. Statistical analysis Continuous variables are expressed as mean and standard deviation or medians and interquartile range, as appropriate. Categorical variables were summarized as absolute number and percentages. Comparisons among groups was performed with Chi squared test and Fisher's test for categorical variables; and Student's T test and Mann-Whitney U test for continuous variables. Box plots and bar plots are also provided for some associations. Mortality in the cohort was described with the use of Kaplan-Meier analysis. Tests were considered significant when the two-tailed p-value was <0.05. We did not correct for multiple comparisons; hence, the widths of the confidence intervals should not be interpreted as definitive for the associations with the outcomes. Association between time to tocilizumab administration and mortality were assessed by means of Cox proportional hazards regression. Missing urea and bilirubin levels on admission were assumed normal for CURB-65 and SOFA calculation; no other imputation was made for missing data. Analysis was performed with Stata 15.1 software (StataCorp). Study oversight The study was designed and conducted by the investigators from the Vall d'Hebron COVID-19 Prospective Cohort Study. Data were collected, debugged, analysed and interpreted by the authors. The institutional review board provided ethical clearance (local

review board code number: PR(AG)183/2020). Patients were asked for an oral consent. The institutional review board granted an informed consent waiver if patients were unable to give oral consent. The manuscript was prepared according to the STROBE guidelines recommendations. All the authors reviewed the manuscript and vouch for the accuracy and completeness of the data and for the adherence of the study to the protocol.

Patient and Public Involvement

Due to the current emergency of the SARS-CoV-2 pandemic, patients were not involved in the design and the conduct of the study, including the selection of the outcomes and recruitment criteria.

RESULTS:

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

Demographic and clinical characteristics Since the onset of the COVID-19 outbreak until March 25th, 3242 respiratory-derived samples have been requested from our institution for COVID-19 diagnosis. Samples were requested from the emergency room and hospitalization wards, as well as from the health care worker surveillance strategy plan. From them, 941 were positive (29%). During this period, 82 SARS-CoV-2 infected patients received at least one dose of tocilizumab. The mean (±SD) age was 59.1 (±19.8) years (95% Confidence Interval 54.8-63.5). Fifty-two patients were male (63.5%). Eighteen (21.9%) patients were born abroad, 13 (16.1%) in Latin America, 3 (3.7%) in Eastern Europe and 2 (2.4%) in North Africa. The mean (±SD) duration of symptoms before hospital admission was 6.7 (±4.4) days. Fever and cough were the main symptoms on admission, occurring in 75 (91.5%) and 71 (86.6%) respectively. Thirty-three (40.3%) patients were former or active tobacco smokers. Coexisting conditions were as follows: 32 (39.0%) had hypertension, 19 (23.5%) had lung diseases (2 (2.4%) asthma, 6 (7.3%) chronic obstructive pulmonary disease among others), 17 (20.7%) had obesity, 16 (19.5%) had diabetes mellitus, 11 (13.6%) had chronic kidney disease, 5 (6.1%) a history of cardiac failure, 1 (1.2%) had cirrhosis. Ten (12.5%) patients were immunosuppressed because of different conditions. Seventy-seven (95.1%) patients had a Barthel scale index of 100 points previous to hospital admission. Table 1 shows demographic and clinical characteristics at baseline. Laboratory and Radiologic finding On admission, mean (±SD) white cell count was 9.2 (10.4) with 17 (21.3%) patients having more than 10000 per cubic millilitre white cells. Lymphocytopenia (<1000 cells per cubic millilitre) was present in 46 (57.5%) patients. Interleukin-6 median (IQR) plasma level on

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

admission was 74.8 (49.4-120.0) ng/ml. Liver enzymes were below five times the upper normal value in all patients. Pneumonia was radiologically proven in all patients on admission or during follow up. Tables 2 and 3 describe laboratory and radiologic and laboratory findings on admission and during follow up. Microbiologic results All included patients had a positive RT-PCR for SARS-CoV-2 in a respiratory-derived sample. On admission, 2 patients out of 56 had a positive pneumococcal urinary antigen result. Sputum samples from 13 patients were sent on admission, bacterial growth was demonstrated in 3 samples, two with *Haemophilus influenzae* that were considered clinically significant and one was deemed contamination with oral bacteria. During the first 7 days follow up, 2 more positive results were retrieved: one Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia coli (considered clinically significant) and one Staphylococcus epidermidis (considered non-clinically significant). Blood samples from 65 patients were sent, and one positive bacterial growth (coagulase-negative Staphylococcus) was observed, although considered a contamination. Detailed microbiologic data are shown in Table 3. Oxygen supplementation and secondary outcomes. Table 4 shows oxygen saturation, oxygen supplementation and ventilation support. On admission, mean FiO2 oxygen supplementation was 0.36 (±0.26) and mean oxygen saturation was 94% (±4.39). Regarding oxygen supplementation devices on admission, 34 (41.5%) patients were on oxygen supplementation: two (5.8%) patients were on nasal cannulas, 22 (64.7%) were using face masks, 9 (26.5%) patients were using high oxygen supplementation devices and 1 (2.9%) patient required endotracheal intubation with mechanical ventilation. Over time, SpO2/FiO2 ratio deteriorated from a median (IOR) of

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

Main outcome and mortality risk factors

428 (316.1-454.8) on admission, 271.4 (158.3-361.5) at 48 hours and 230.2 (118.8-346.4) at 7 days follow up (p<0.001). Fifty-five (69.6%) patients required intensive oxygen therapy, including high flow oxygen delivery systems, high flow nasal cannula, noninvasive mechanical ventilation or invasive ventilation during the study period. Median (IQR) days on high flow oxygen delivery systems, high flow nasal cannula, non-invasive mechanical ventilation or invasive ventilation before progression to other intensive oxygen therapy, outcome attainment or data censoring were 2.0 (1.0-3.0), 4 (2.0-6.0), 3.0 (2.0-4.0) and 9 (9.0-9.0) respectively. The median (IQR) days from admission to first intensive oxygen therapy was 2.0 (1.0-4.5). Only one (1.2%) patient required vasopressor therapy due to hypotension. No patient required renal replacement therapy. Respiratory failure and ARDS developed in 62 (75.6%) and 45 (54.9%) patients, respectively. Median (IQR) days from symptoms to respiratory failure and ARDS were 8 (6.0-11.0) and 8 (5.0-11.0) respectively. Median (IQR) days from admission to respiratory failure and ARDS were 1 (0.0-3.0) and 2 (1.0-4.0) respectively. Secondary outcomes can be found in Table 5. Tocilizumab treatment and concomitant treatment Eighty-one (98.9%) patients received hydroxychloroquine, 63 (76.8%) lopinavir/ritonavir, 21 (25.61%) darunavir/cobicistat, and 79 (96.34%) azithromycin. All patients were initially treated with antibiotic therapy, mainly ceftriaxone (77 (93.9%) patients). As expressed before, all patients received at least one dose of tocilizumab. Median (IQR) time in days from symptom onset to tocilizumab administration was 9.0 (6.0-11.0) and from admission to tocilizumab administration was 2.0 (1.0-3.0)). Other treatments include cytokine hemoadsorption therapy in 2 (2.4%) patients in ICU.

Table 6 summarizes main outcome in the study population. At the end of the follow up period, of the 82 patients 34 (41.5%) had been discharged, 22 (26.8%) had died, 14 (17.1%) were hospitalized in ICU, 9 (11.0%) were hospitalized in medical wards, and 3 (3.7%) had been transferred to another institution. In the univariate analysis age, age-adjusted Charlson comorbidity index, medical history of active or former solid cancer, hypertension, history of heart failure, chronic kidney disease and worse age-adjusted Charlson index at baseline were associated with increased risk of mortality (Table 7). By 7-day follow-up, the mortality rate was 4.0% per person-day (95% confidence interval [CI], 2.4% to 6.2%) by Kaplan-Meier analysis. Mortality was more frequent in patients receiving tocilizumab once ARDS was present (hazard ratio for mortality 3.3; 95% CI, 1.3 to 8.5; age-adjusted hazard ratio for mortality 2.1; 95% CI, 0.8 to 5.8)(Figure 1) or respiratory failure was present (hazard ratio for mortality 3.13; 95% CI, 1.3 to 7.8; age-adjusted hazard ratio for mortality 2.4; 95% CI, 0.9 to 6.4)(Figure 2). When dividing patients according to the nearest SpO2/FiO2 ratio to tocilizumab administration, mortality was higher among patients with lower SpO2/FiO2 ratio (SpO2/FiO2 ratio < 200, 46.2%; SpO2/FiO2 ratio 200-300, 16.7%; SpO2/FiO2 ratio >300, 20.6%; p=0.03)(Figure 3). Distribution of the nearest SpO2/FiO2 ratio to tocilizumab administration depending on outcome groups was not statistically significant (mean (SD) SpO2/FiO2 ratio: 321.3 (154.7) dead, 343.1 (132.7) ICU, 396.9 (96.2) alive; p=0.2)(Figure 4). No correlation was observed between nearest IL-6 levels to tocilizumab administration and main outcome (median (IQR) IL-6 levels: 79.7 (48.2-128.1) dead, 77.5 (55-120) ICU admission, 71.4 (49.4-116) alive; p=0.92). Basal characteristics of patients stratified by ARDS and respiratory failure can be found in the Supplementary Appendix.

Safety

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

Twelve (14.63%) out of 82 patients reported a total of 14 adverse events during the follow up. Thirteen (92.9%) adverse events were considered related with lopinavir/ritonavir, 9 (75.0%) patients discontinued lopinavir/ritonavir treatment due to gastrointestinal symptoms. Diarrhoea was the most common reported adverse event. Other adverse events included nausea and dysuria. There were no adverse events attributed to tocilizumab. No serious adverse events were reported during follow up, and only 2 (14.3%) were considered moderate. Eleven (91.7%) patients recovered without medical sequelae and one patient had an unknown outcome. No tocilizumab discontinuation was reported due to adverse events.

DISCUSSION

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

This preliminary report from the Vall d'Hebron COVID-19 Prospective Cohort Study describes the characteristics and clinical outcomes of patients who were hospitalized in non-ICU wards and received treatment with tocilizumab. Our results show that a timely administration of immune-modulating therapies, before the onset of respiratory insufficiency or ARDS, can improve severe COVID-19 patients' outcomes with a threefold reduction in 7-day mortality. Therapies to improve outcomes of patients with COVID-19 focus on viral-directed therapies and host-directed therapies. There is still lack of evidence about the efficacy of any of these therapies, although this does not prevent physicians to use all sort of off-label therapies despite the risk of serious adverse events. ²⁶ Therapies to curb uncontrolled cytokine release have been proposed and are being widely used. Randomized controlled trials with host-directed therapies are currently under way and results will be available within the next months. ^{17,18} Meanwhile, data from prospective studies can help to improve COVID-19 patients management. In our study, the 7-day mortality was 26.8%, slightly higher than a recent experience with remdesivir and similar to the mortality of 22.1% reported in another study with lopinavir/ritonavir.^{27,28} However, the patients in our prospective cohort had more coexisting conditions, including potential mortality risk factors such as hypertension, other cardiovascular and metabolic diseases, chronic kidney disease and cancer. The understanding of mortality risk factors in patients with COVID-19 is an evolving matter. Age, specific coexisting conditions and laboratory parameters may help identifying patients with poor outcome.²⁹ As expressed before, in our cohort of patients treated with tocilizumab, hypertension, history of cardiac failure and chronic kidney disease were

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

associated with higher mortality in the univariate analysis. Antihypertensive agents, such as angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB), have been suggested to be associated with the increase mortality observed in this subset of patients. Angiotensin converting enzyme 2 plays an important role in SARS-CoV-2 viral entry as co-receptor.³⁰ Hypothesis outline that the interactions between these drugs and co-receptors may increase viral spreading in the lung and pose the patients at a higher risk of death. However, the evidence is limited and no specific recommendations could be drawn from current evidence, especially when ACEI and ARB have shown to reduce mortality in this at risk population.³¹ The Vall d'Hebron COVID-19 Prospective Cohort Study has among its main objectives to analyse the role of these and other drugs used to treat chronic conditions in the prognosis of patients with COVID-19. Host-directed therapies aiming at blocking an unrestrained immune response and an excessive inflammation have been proposed as potential therapies to prevent acute lung injury and subsequent ARDS. SARS-CoV-2 infection severity has been associated with an increase in IL-6 and D dimer levels, and the cytokine profile resembles that of other conditions in which host-directed therapies have been successfully used. 13,29,32 Timely use of host-directed therapies may curb uncontrolled cytokine release and prevent damage inflicted by hyperinflammation. Tocilizumab has shown to be safe in two small Chinese cohort studies of patients with COVID-19.9,16 Efficacy of tocilizumab, measured as hospital discharge, was 90.5% (19 out of 21 patients) in patients with COVID-19 needing oxygen supplementation and having elevated IL-6 in one study⁹; while the other study showed 3 deaths, 10 clinical stabilizations and 2 clinical aggravation out of 15 patients. 16 Other laboratory and radiologic findings also improved in a short period of time. However, standard of care in the studies was different limiting the possibility of direct comparisons.

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

As in other infections and inflammation-driven diseases, timely initiation of precise therapy is the mainstay of patient management and directly affects mortality and morbidity. Our study showed that patients receiving prompt treatment with tocilizumab before lung injury is established have less 7-day mortality, a benefit that may be sustained in the long-term.³³ The safety profile of tocilizumab has been extensively studied in clinical trials with patients suffering autoimmune diseases. The most common adverse events of intravenous tocilizumab in a pooled analysis of 3 clinical trials were upper respiratory infections, nasopharyngitis, headache, hypertension and increase in liver enzymes. Serious adverse events occurred in 12% of the patients, being infectious diseases the most common.³⁴ In our study we did not report any serious adverse event, although the symptoms of systemic viral infections may mimic any adverse event and difficult its identification. Tozilizumab-related bacterial infections were not reported in our study. Two factors may have contributed to this: first, many patients were under antibiotic treatment, and second, the short follow up period precludes us from any further analysis. Nevertheless, the low cumulative dose administered in this subset of patients may diminish the likelihood of infectious adverse events. In a time of scarce medical resources, including limited stock of host-directed therapies, hard medical decisions have to be done by first-line physicians. Allocation of therapies to patients with the highest chances of a favourable outcome should be encouraged, maximizing the benefit of the intervention.³⁵ Evidence-based decision-making and benefitmaximizing allocation of the available resources should be promoted. In this regards our study can help physicians to better allocate host-directed therapy in patients with COVID-19 prioritizing moderate-to-severe ill patients over critically ill patients.

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

This preliminary exploratory study has several limitations. First, there is no control group and the minimum follow up period was 7 days. Therefore, at this point it is not possible to evaluate the differences between patients receiving tocilizumab or not and, consequently, it is not possible to evaluate solidly what is the overall benefit of administering this drug. However, the urgency of obtaining data on new therapies justifies the early communication of these results. Second, ICU admission is not a very robust endpoint since it depends on the attitudes of the treating physicians as well as the availability of beds at times of resource scarcity and overwhelming demand. For this reason, mortality was selected as the main outcome in our study. Besides, the subsequent analysis of all patients included in the Vall d'Hebron COVID-19 Prospective Cohort Study may solve this limitation and inform results with a longer follow up period. Finally, our data is limited to a single centre. While our results may not be extrapolated to other populations or other standards of care, the management of patients was homogeneous avoiding the centre effect of multicentric studies. Multivariate analysis is limited by sample size. In summary, we found a mortality rate of 26.8% in this subset of patients with COVID-19 receiving tocilizumab for the treatment of inflammatory-related lung injury. Time from lung injury onset to tocilizumab administration may be critical to patient recovery. Our results may help front line physician to make evidence-based decisions in times of scarce resources and operationalized fair and transparent allocation procedures, maximizing the benefit of the intervention. Future and current host-directed clinical trials for patients with COVID-19 should consider our preliminary data in their design. All our patients were treated with a combination of antiviral drugs whose efficacy is yet to be demonstrated. Host-directed therapies in the absence of antiviral drugs needs further investigation.

501 REFERENCES 502 503 1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet Lond Engl 2020;395(10223):497-506. 504 Novel Coronavirus (2019-nCoV) situation reports [Internet]. [cited 2020 Apr 505 2. 506 1]; Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports 507 Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. [The 508 epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases 509 (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi Zhonghua 510 511 Liuxingbingxue Zazhi 2020;41(2):145-51. Hauser A, Counotte MJ, Margossian CC, et al. Estimation of SARS-CoV-2 mortality 512 4. during the early stages of an epidemic: a modelling study in Hubei, China and 513 northern Italy. medRxiv 2020;2020.03.04.20031104. 514 5. De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus 515 infections. Expert Rev Anti Infect Ther 2006;4(2):291-302. 516 517 6. Al-Tawfiq JA, Memish ZA. Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Expert Rev Anti Infect Ther 518 2017;15(3):269-75. 519 Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a 520 treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J 521 Antimicrob Agents 2020;105949. 522 Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with 523 COVID-19: results of a randomized clinical trial. medRxiv 524 525 2020;2020.03.22.20040758. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with 526 tocilizumab. Available from: chinaXiv:202003.00026v1 (2020). 527 www.chinaxiv.org/abs/202003.00026 528 10. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated 529 530 with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost JTH 2020; 531 11. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-

nCoV acute respiratory disease. Lancet Lond Engl 2020;395(10223):e30–1.

- 12. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19:
- consider cytokine storm syndromes and immunosuppression. The Lancet
- 536 2020;395(10229):1033-4.
- 13. Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-
- 538 nCoV: host-directed therapies should be an option. Lancet Lond Engl
- 539 2020;395(10224):e35–6.
- 540 14. Biggioggero M, Crotti C, Becciolini A, Favalli EG. Tocilizumab in the treatment of
- rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Devel
- 542 Ther 2019;13:57–70.
- 543 15. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells:
- recognition and management. Blood 2016;127(26):3321–30.
- 16. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a
- single center experience. J Med Virol 2020;
- 547 17. Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With
- 548 COVID-19 Full Text View ClinicalTrials.gov [Internet]. [cited 2020 Apr
- 549 11]; Available from: https://clinicaltrials.gov/ct2/show/NCT04315298
- 18. Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia Full
- Text View ClinicalTrials.gov [Internet]. [cited 2020 Apr 11]; Available from:
- https://clinicaltrials.gov/ct2/show/NCT04331665
- 19. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired
- pneumonia severity on presentation to hospital: an international derivation and
- validation study. Thorax 2003;58(5):377–82.
- 556 20. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of Clinical Criteria for Sepsis.
- 557 JAMA 2016;315(8):762–74.
- 558 21. World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-
- nCoV) in suspected human cases. WHO Interim Guid 2020;2019(January):1–7.
- 560 22. Moës E, Vijgen L, Keyaerts E, et al. A novel pancoronavirus RT-PCR assay: frequent
- detection of human coronavirus NL63 in children hospitalized with respiratory tract
- infections in Belgium. BMC Infect Dis 2005;5:6.
- 563 23. Woo PCY, Lau SKP, Lam CSF, et al. Discovery of a novel bottlenose dolphin
- coronavirus reveals a distinct species of marine mammal coronavirus in
- 565 Gammacoronavirus. J Virol 2014;88(2):1318–31.
- 566 24. Force TADT. Acute Respiratory Distress Syndrome: The Berlin Definition. JAMA
- 567 2012;307(23):2526–33.

- 568 25. Festic E, Bansal V, Kor DJ, Gajic O. SpO2/FiO2 Ratio on Hospital Admission Is an
- Indicator of Early Acute Respiratory Distress Syndrome Development Among
- Patients at Risk. J Intensive Care Med 2013;30(4):209–16.
- 571 26. Kalil AC. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and
- Randomized Clinical Trials During Pandemics. JAMA 2020;
- 573 27. Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients
- with Severe Covid-19. N Engl J Med 2020;
- 575 28. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized
- with Severe Covid-19. N Engl J Med 2020;
- 577 29. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult
- inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet
- 579 Lond Engl 2020;395(10229):1054–62.
- 580 30. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new
- coronavirus of probable bat origin. Nature 2020;579(7798):270–3.
- 31. Patel AB, Verma A. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and
- Angiotensin Receptor Blockers: What Is the Evidence? JAMA 2020;
- 32. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and
- management of cytokine release syndrome. Blood 2014;124(2):188–95.
- 586 33. Ngai JC, Ko FW, Ng SS, To K-W, Tong M, Hui DS. The long-term impact of severe
- 587 acute respiratory syndrome on pulmonary function, exercise capacity and health
- status. Respirol Carlton Vic 2010;15(3):543–50.
- 589 34. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term
- safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in
- monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of
- safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68(10):1580–4.
- 593 35. Emanuel EJ, Persad G, Upshur R, et al. Fair Allocation of Scarce Medical Resources
- in the Time of Covid-19. N Engl J Med 2020;

597 **TABLES**

598

Table 1. Demographic and clinical characteristics of the patients at baseline*

Age, mean - yr 59.1 ±19.8 Sex - no (%) 52 (63.4%) Female 30 (36.6%) Origin 30 (36.6%) Spain 63 (77.8%) Latin America 13 (16.1%) East Europe 3 (3.7%) North Africa (Magreb) 2 (2.4%) Coexisting condition - no (%) 66.1%) Active tabacco smoker 5 (6.1%) Former tabacco smoker 28 (34.2%) Never smoke 49 (59.8%) Active daily alcohol consumption 1 (1.2%) Former daily alcohol consumption 2 (2.4%) Never drink daily 79 (96.3%) Cognitive imparment 1 (1.2%) Diabetes Mellitus 16 (19.5%) Immunosuppression 10 (12.2%) Solid organ transplant 5 (6.1%) Drug induced immunosuppression 3 (3.7%) Bone marrow transplant 1 (1.2%) Other 1 (1.2%) Former cancer (includes any solid cancer) 9 (11.1%) Active cancer (includes any solid cancer) 2 (2.4%) Former haematological con	Characteristics	Patients (n=82)
Sex - no (%) Male 52 (63.4%) Female 30 (36.6%) Spain 63 (77.8%) Latin America 13 (16.1%) East Europe 3 (3.7%) North Africa (Magreb) 2 (2.4%) Coexisting condition - no (%) Active tabacco smoker 5 (6.1%) Former tabacco smoker 28 (34.2%) Never smoke 49 (59.8%) Active daily alcohol consumption 1 (1.2%) Former daily alcohol consumption 2 (2.4%) Cognitive imparment 1 (1.2%) Solid organ transplant 16 (19.5%) Immunosuppression 10 (12.2%) Solid organ transplant 1 (1.2%) Solid organ transplant 1 (1.2%) Solid organ transplant 1 (1.2%) Cother 2 (2.4%) Cother 3 (3.7%) Cother 4 (1.2%) Cother 5 (6.1%) Cother 6 (6.1%) Co	Age, mean - yr	, ,
Male 52 (63.4%) Female 30 (36.6%) Origin Spain Latin America 13 (16.1%) East Europe 3 (3.7%) North Africa (Magreb) 2 (2.4%) Coexisting condition – no (%) Active tabacco smoker Former tabacco smoker 5 (6.1%) Former tabacco smoker 28 (34.2%) Never smoke 49 (59.8%) Active daily alcohol consumption 1 (1.2%) Former daily alcohol consumption 2 (2.4%) Never drink daily 79 (96.3%) Cognitive imparment 1 (1.2%) Diabetes Mellitus 16 (19.5%) Immunosuppression 10 (12.2%) Solid organ transplant 5 (6.1%) Drug induced immunosuppression 3 (3.7%) Bone marrow transplant 1 (1.2%) Other 1 (1.2%) Former cancer (includes any solid cancer) 2 (2.4%) Former haematological condition (includes leukemia and lymphoma) 3 (3.7%) Hystory of cardiac failure 5 (6.1%) Hystory of cardiac failure 5 (6.1%)		
Female 30 (36.6%) Origin Spain 63 (77.8%) Latin America 13 (16.1%) East Europe 3 (3.7%) North Africa (Magreb) 2 (2.4%) Coexisting condition – no (%) Active tabacco smoker Active tabacco smoker 5 (6.1%) Former tabacco smoker 28 (34.2%) Never smoke 49 (59.8%) Active daily alcohol consumption 1 (1.2%) Former daily alcohol consumption 2 (2.4%) Never drink daily 79 (96.3%) Cognitive imparment 1 (1.2%) Diabetes Mellitus 16 (19.5%) Immunosuppression 10 (12.2%) Solid organ transplant 5 (6.1%) Drug induced immunosuppression 3 (3.7%) Bone marrow transplant 1 (1.2%) Former cancer (includes any solid cancer) 9 (11.1%) Active cancer (includes any solid cancer) 9 (11.1%) Active cancer (includes any solid cancer) 2 (2.4%) Former haematological condition (includes leukemia and lymphoma) 2 (2.4%) Hypertension 32 (39%)	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	52 (63.4%)
Spain 63 (77.8%) Latin America 13 (16.1%) East Europe 3 (3.7%) North Africa (Magreb) 2 (2.4%) Coexisting condition – no (%) Active tabacco smoker 5 (6.1%) Former tabacco smoker 28 (34.2%) Never smoke 49 (59.8%) Active daily alcohol consumption 1 (1.2%) Former daily alcohol consumption 2 (2.4%) Never drink daily 79 (96.3%) Cognitive imparment 1 (1.2%) Diabetes Mellitus 16 (19.5%) Immunosuppression 10 (12.2%) Solid organ transplant 5 (6.1%) Drug induced immunosuppression 3 (3.7%) Bone marrow transplant 1 (1.2%) Other 1 (1.2%) Former cancer (includes any solid cancer) 9 (11.1%) Active cancer (includes any solid cancer) 2 (2.4%) Former haematological condition (includes leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension 32 (39%) Hystory of cardiac failure 5 (6.1%) Atrial fibrillation 10 (12.2%) Lung diseases ¬ 19 (23.5%)	Female	
Spain 63 (77.8%) Latin America 13 (16.1%) East Europe 3 (3.7%) North Africa (Magreb) 2 (2.4%) Coexisting condition – no (%) Active tabacco smoker 5 (6.1%) Former tabacco smoker 28 (34.2%) Never smoke 49 (59.8%) Active daily alcohol consumption 1 (1.2%) Former daily alcohol consumption 2 (2.4%) Never drink daily 79 (96.3%) Cognitive imparment 1 (1.2%) Diabetes Mellitus 16 (19.5%) Immunosuppression 10 (12.2%) Solid organ transplant 5 (6.1%) Drug induced immunosuppression 3 (3.7%) Bone marrow transplant 1 (1.2%) Other 1 (1.2%) Former cancer (includes any solid cancer) 9 (11.1%) Active cancer (includes any solid cancer) 2 (2.4%) Former haematological condition (includes leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension 32 (39%) Hystory of cardiac failure 5 (6.1%) Atrial fibrillation 10 (12.2%) Lung diseases ¬ 19 (23.5%)	Origin	
Latin America 13 (16.1%) East Europe 3 (3.7%) North Africa (Magreb) 2 (2.4%) Coexisting condition – no (%) Active tabacco smoker 5 (6.1%) Former tabacco smoker 49 (59.8%) Active daily alcohol consumption 1 (1.2%) Former daily alcohol consumption 2 (2.4%) Never drink daily 79 (96.3%) Cognitive imparment 1 (1.2%) Diabetes Mellitus 16 (19.5%) Immunosuppression 10 (12.2%) Solid organ transplant 5 (6.1%) Drug induced immunosuppression 3 (3.7%) Bone marrow transplant 1 (1.2%) Other 1 (1.2%) Former cancer (includes any solid cancer) 9 (11.1%) Active cancer (includes any solid cancer) 2 (2.4%) Former haematological condition (includes leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension 10 (12.2%) Atrial fibrillation 10 (12.2%) Lung diseases ¬ 19 (23.5%)		63 (77.8%)
North Africa (Magreb) Coexisting condition – no (%) Active tabacco smoker Former tabacco smoker Sever smoke Active daily alcohol consumption Former daily alcohol consumption Former daily alcohol consumption Cognitive imparment Diabetes Mellitus Induced immunosuppression Bone marrow transplant Other Former cancer (includes any solid cancer) Active cancer (includes any solid cancer) Former haematological condition (includes leukemia and lymphoma) Hystory of cardiac failure Atrial fibrillation Log (34.2%) 5 (6.1%) 6 (7.2%)	-	
North Africa (Magreb) Coexisting condition – no (%) Active tabacco smoker Former tabacco smoker Sever smoke Active daily alcohol consumption Active daily alcohol consumption Former daily alcohol consumption Cognitive imparment Diabetes Mellitus Induced immunosuppression Bone marrow transplant Other Former cancer (includes any solid cancer) Active cancer (includes any solid cancer) Former haematological condition (includes leukemia and lymphoma) Hystory of cardiac failure Atrial fibrillation Log (34.2%) 5 (6.1%) 5 (6.1%) 5 (6.1%) 1 (1.2%) 5 (6.1%) 5 (6.1%) 5 (6.1%) 5 (6.1%) 5 (6.1%) 5 (6.1%) 5 (6.1%) 5 (6.1%) 5 (6.1%) 5 (6.1%) 5 (6.1%) 5 (6.1%) 5 (6.1%) 5 (6.1%) 5 (6.1%) 5 (6.1%) 5 (6.1%) 5 (6.1%) 6 (7.2%)	East Europe	3 (3.7%)
Coexisting condition – no (%) Active tabacco smoker Former tabacco smoker 28 (34.2%) Never smoke 49 (59.8%) Active daily alcohol consumption 1 (1.2%) Former daily alcohol consumption 2 (2.4%) Never drink daily 79 (96.3%) Cognitive imparment 1 (1.2%) Diabetes Mellitus 16 (19.5%) Immunosuppression 5 (6.1%) Drug induced immunosuppression 3 (3.7%) Bone marrow transplant 5 (6.1%) Other 1 (1.2%) Other 1 (1.2%) Former cancer (includes any solid cancer) Active cancer (includes any solid cancer) Former haematological condition (includes leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension 4 (2.4%) Atrial fibrillation 10 (12.2%) Lung diseases ¬ 19 (23.5%)		
Active tabacco smoker Former tabacco smoker Rever smoke Active daily alcohol consumption Former daily alcohol consumption Former daily alcohol consumption Permer daily alcohol consumption Rever drink daily Permer daily alcohol consumption Rever drink daily Permer daily alcohol consumption Rever drink daily Permer diver drink daily Permer diver drink daily Rever drink daily Permer deli daily Permer deli daily Rever drink daily Permer deli daily Rever drink daily Permer deli daily Rever daily Permer daily Permer deli d		
Former tabacco smoker Never smoke Active daily alcohol consumption Former daily alcohol consumption 1 (1.2%) Former daily alcohol consumption 2 (2.4%) Never drink daily 79 (96.3%) Cognitive imparment 1 (1.2%) Diabetes Mellitus 16 (19.5%) Immunosuppression 10 (12.2%) Solid organ transplant 5 (6.1%) Drug induced immunosuppression 3 (3.7%) Bone marrow transplant 1 (1.2%) Other 1 (1.2%) Former cancer (includes any solid cancer) Active cancer (includes any solid cancer) Former haematological condition (includes leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension 32 (39%) Hystory of cardiac failure 5 (6.1%) Atrial fibrillation 10 (12.2%) Lung diseases ¬ 19 (23.5%)		5 (6.1%)
Never smoke Active daily alcohol consumption Former daily alcohol consumption 2 (2.4%) Never drink daily 79 (96.3%) Cognitive imparment 1 (1.2%) Diabetes Mellitus 16 (19.5%) Immunosuppression 10 (12.2%) Solid organ transplant 5 (6.1%) Drug induced immunosuppression 3 (3.7%) Bone marrow transplant 1 (1.2%) Other 1 (1.2%) Former cancer (includes any solid cancer) Active cancer (includes any solid cancer) Former haematological condition (includes leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension 32 (39%) Hystory of cardiac failure 5 (6.1%) Atrial fibrillation 10 (12.2%) Lung diseases ¬ 19 (23.5%)	Former tabacco smoker	
Active daily alcohol consumption Former daily alcohol consumption 2 (2.4%) Never drink daily 79 (96.3%) Cognitive imparment 1 (1.2%) Diabetes Mellitus 16 (19.5%) Immunosuppression 10 (12.2%) Solid organ transplant 5 (6.1%) Drug induced immunosuppression 3 (3.7%) Bone marrow transplant 1 (1.2%) Other 1 (1.2%) Former cancer (includes any solid cancer) Active cancer (includes any solid cancer) Former haematological condition (includes leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension 32 (39%) Hystory of cardiac failure 5 (6.1%) Atrial fibrillation 10 (12.2%) Lung diseases ¬ 19 (23.5%)	Never smoke	
Former daily alcohol consumption Never drink daily Cognitive imparment 1 (1.2%) Diabetes Mellitus 16 (19.5%) Immunosuppression Solid organ transplant Drug induced immunosuppression Bone marrow transplant Other 1 (1.2%) Former cancer (includes any solid cancer) Active cancer (includes any solid cancer) Former haematological condition (includes leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension Hystory of cardiac failure Atrial fibrillation Lung diseases ¬ 1 (1.2%) 1 (2.4%) 1 (2.4%) 1 (2.4%) 1 (2.4%) 1 (2.4%) 1 (2.4%) 1 (2.4%) 1 (2.4%) 1 (2.4%) 1 (2.4%)		, , ,
Never drink daily Cognitive imparment 1 (1.2%) Diabetes Mellitus 16 (19.5%) Immunosuppression Solid organ transplant Drug induced immunosuppression Bone marrow transplant Other 1 (1.2%) Former cancer (includes any solid cancer) Active cancer (includes any solid cancer) Former haematological condition (includes leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension Atrial fibrillation 10 (12.2%) 10 (12.2%) 10 (12.2%) Lung diseases ¬ 10 (12.9%) 10 (12.2%) 11 (1.2%) 12 (2.4%) 13 (3.7%) 14 (2.4%) 15 (6.1%) 16 (1.2%) 17 (23.5%)		,
Cognitive imparment Diabetes Mellitus 16 (19.5%) Immunosuppression 10 (12.2%) Solid organ transplant 5 (6.1%) Drug induced immunosuppression 3 (3.7%) Bone marrow transplant 1 (1.2%) Other 1 (1.2%) Former cancer (includes any solid cancer) Active cancer (includes any solid cancer) Former haematological condition (includes leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension 10 (12.2%) Atrial fibrillation 10 (12.2%) Lung diseases ¬ 19 (23.5%)	Never drink daily	79 (96.3%)
Diabetes Mellitus Immunosuppression Solid organ transplant Drug induced immunosuppression Bone marrow transplant Other 1 (1.2%) Former cancer (includes any solid cancer) Active cancer (includes any solid cancer) Former haematological condition (includes leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension Atrial fibrillation Lung diseases ¬ 10 (12.2%) 5 (6.1%) 10 (12.2%)		
Solid organ transplant Drug induced immunosuppression 3 (3.7%) Bone marrow transplant 1 (1.2%) Other 1 (1.2%) Former cancer (includes any solid cancer) Active cancer (includes any solid cancer) Former haematological condition (includes leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension Hypertension 32 (39%) Hystory of cardiac failure 5 (6.1%) Atrial fibrillation 10 (12.2%) Lung diseases ¬ 19 (23.5%)		
Solid organ transplant Drug induced immunosuppression 3 (3.7%) Bone marrow transplant 1 (1.2%) Other 1 (1.2%) Former cancer (includes any solid cancer) Active cancer (includes any solid cancer) Former haematological condition (includes leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension 32 (39%) Hystory of cardiac failure 5 (6.1%) Atrial fibrillation 10 (12.2%) Lung diseases ¬ 19 (23.5%)	Immunosuppression	10 (12.2%)
Drug induced immunosuppression 3 (3.7%) Bone marrow transplant 1 (1.2%) Other 1 (1.2%) Former cancer (includes any solid cancer) 9 (11.1%) Active cancer (includes any solid cancer) 2 (2.4%) Former haematological condition (includes leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension 32 (39%) Hystory of cardiac failure 5 (6.1%) Atrial fibrillation 10 (12.2%) Lung diseases ¬ 19 (23.5%)		5 (6.1%)
Bone marrow transplant Other 1 (1.2%) Former cancer (includes any solid cancer) Active cancer (includes any solid cancer) Former haematological condition (includes leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension Hystory of cardiac failure Atrial fibrillation 10 (12.2%) Lung diseases ¬ 19 (23.5%)		
Other 1 (1.2%) Former cancer (includes any solid cancer) 9 (11.1%) Active cancer (includes any solid cancer) 2 (2.4%) Former haematological condition (includes leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension 32 (39%) Hystory of cardiac failure 5 (6.1%) Atrial fibrillation 10 (12.2%) Lung diseases ¬ 19 (23.5%)		
Former cancer (includes any solid cancer) Active cancer (includes any solid cancer) Former haematological condition (includes leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension Hystory of cardiac failure Atrial fibrillation 10 (12.2%) Lung diseases ¬ 9 (11.1%) 9 (11.1%) 3 (3.7%) 2 (2.4%) 5 (2.4%) 10 (2.4%) 10 (12.2%) 19 (23.5%)		
Active cancer (includes any solid cancer) Former haematological condition (includes leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension Hystory of cardiac failure Atrial fibrillation Lung diseases ¬ 2 (2.4%) 2 (2.4%) 2 (2.4%) 5 (6.1%) 10 (12.2%) 19 (23.5%)	Former cancer (includes any solid cancer)	
Former haematological condition (includes leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension Hystory of cardiac failure Atrial fibrillation Lung diseases ¬ 19 (23.5%)	Active cancer (includes any solid cancer)	2 (2.4%)
leukemia and lymphoma) Active haematological condition (includes leukemia and lymphoma) Hypertension Hystory of cardiac failure Atrial fibrillation Lung diseases ¬ 19 (23.5%)		
leukemia and lymphoma)32 (39%)Hypertension5 (6.1%)Hystory of cardiac failure5 (6.1%)Atrial fibrillation10 (12.2%)Lung diseases ¬19 (23.5%)		
leukemia and lymphoma)32 (39%)Hypertension5 (6.1%)Hystory of cardiac failure5 (6.1%)Atrial fibrillation10 (12.2%)Lung diseases ¬19 (23.5%)	Active haematological condition (includes	2 (2.4%)
Hystory of cardiac failure5 (6.1%)Atrial fibrillation10 (12.2%)Lung diseases ¬19 (23.5%)	leukemia and lymphoma)	
Atrial fibrillation 10 (12.2%) Lung diseases ¬ 19 (23.5%)	Hypertension	32 (39%)
Lung diseases ¬ 19 (23.5%)	Hystory of cardiac failure	5 (6.1%)
	Atrial fibrillation	10 (12.2%)
Chronic obstructive pulmonary disease 6 (7.3%)	Lung diseases ¬	19 (23.5%)
	Chronic obstructive pulmonary disease	6 (7.3%)
Obstructive sleep apnea syndrome 3 (3.7%)	Obstructive sleep apnea syndrome	3 (3.7%)
Insterstitial lung disease 2 (2.4%)	Insterstitial lung disease	2 (2.4%)
Asthma 2 (2.4%)		2 (2.4%)
Bronchiectasis 2 (2.4%)	Bronchiectasis	2 (2.4%)
Lung restritive disease 2 (2.4%)	Lung restritive disease	2 (2.4%)
Lung transplant 2 (2.4%)	Lung transplant	2 (2.4%)
Pulmonary hypertension 1 (2.4%)		1 (2.4%)
Controlled pulmonary tuberculosis 1 (2.4%)	Controlled pulmonary tuberculosis	1 (2.4%)
Chronic kidney disease 11 (13.6%)		11 (13.6%)
GFR>50 3 (27.3%)	GFR>50	3 (27.3%)

GFR 30-50	4 (36.4%)
GFR<30	4 (36.4%)
Renal supportive therapy (hemodyalisis)	2 (18.2%)
Cirrhosis	1 (1.2%)
Central nervous system disease	2 (2.4%)
Obesity	17 (20.7%)
Mean duration of symptom before	6.7 ±4.4
admission (days)	
Mean days from symptom onset to	1.14 ±3.6
dyspnea	
Mean duration of dyspnea before	3.48±3.2
admission	
Symptoms	
Fever	75 (91.5%)
Cough	71 (86.6%)
Shortness of breath	54 (65.9%)
Sore throat	1 (1.2%)
Sputum production	8 (9.8%)
Rhinorrhea	1 (1.2%)
Headache	1 (1.2%)
Lost of weigth	4 (4.9%)
Malaise	46 (56.1%)
Hemoptysis	5 (6.1%)
Chest pain	21 (25.6%)
Anosmia	4 (4.9%)
Cacosmia	3 (3.7%)
Muscle and joint pain	14 (17.1%)
Nauseas	3 (3.7%)
Vomits	36 (43.9%)
Diarrhea	8 (9.8%)
Profuse sweating	2 (2.4%)
Barthel scale 100 previous to symptoms	77 (93.9%)
onset†	
ECOG ≤ 1 previous to symtoms onset ‡	78 (95.1%)
Median (IQR), age-adjusted Charlson	3 (1-4)
index at baseline - points	1.00
Median (IQR), SOFA index at admission	1 (0-3)
- points ¶	10 (000()
CURB-65 ≥ 3 §	18 (22%)

*Plus-minus values are means (±SD). Rounding has been applied to percentages. Total may no be 100 because of rounding.

†Barthel index total scores range from 0 to 100, with higher scores indicating a better performance of 10 basic daily self-care activities. ‡ The Eastern Cooperative Oncolgy Group (ECOG) performance scale range from 0 (fully active) to 4 (completely disabled). ∫ The Charlson risk index score ranges from 0 to 37 with higher scores indicating a higher risk of death. ¶ Sequential Organ Failure Assessment (SOFA) score ranges from 0 to 24 with higher ranges indicating a higher risk or morbidity; individuals with a score of 15 or

more have a mortality rate of 90%. Its calculation is missing in two patients. § Community acquired pneumonia severity index assessing Confusion, Urea, Respiratory rate, Blood pressure and age over 65 years (CURB-65) ranges from 0 to 5 depending on the number of risk factors present in the same patient.

GFR: glomerular filtration rate.

¬ One patient had insterstitial lung disease and pulmonary hypertension and another

patient had obtructive sleep apnea syndrome and lung restrictive disease.

Table 2. Status on admission and follow up*

	Admission (n=82) †	48 hours (n=79)	7 days (n=51) †
		†	
Vital signs on admission – no. (%)			
Systolic blood pressure, mean - mmHg	128.3±18.3	120.8 ±17.7	125.0 ±19.4
Diastolic blood pressure, mean - mmHg	73 ±12.2	71.3 ±9.3	72.3 ±10.7
Temperature, mean - °C	37.7 ±0.9	36.8 ±0.8	36.4 ±0.7
Heart rate, mean - rates per minute	94.3 ±17.8	79.7 ±12.0	79.0 ±14.2
Respiratory rate, mean - breaths per	23.9 ±6.3	21.5 ±6.0	22.5 ±11.5
minute			
Temperature > 37.8°C	34 (42.5%)	9 (12.1%)	1 (1.6%)
Heart rate > 100 beats per minute	28 (65.4%)	3 (3.8%)	7 (11.5%)
Respiratory rate > 20 breaths per minute	39 (58.2%)	24 (40%)	23 (46.9%)
Oxygen saturation, mean	94.0 ±4.4	94.1 ±3.9	93.6 ±6.9
Physical examination – no. (%)			
Glasgow coma scale of 15	82 (100%)		
Abnormal lung sounds			
Crackles	62 (75.6%)	54 (67.5%)	39 (58.2%)
Hypophonesis	9 (11%)	7 (8.6%)	5 (7.5%)
Wheezing	5 (6.1%)	2 (2.5%)	0 (0%)
Rhonchus	5 (6.1%)	2 (2.5%)	2 (3%)
Imaging characteristics – no. (%)			
Type of chest radiography alteration†			
Unilateral or bilateral infiltrate	20 (24.4%)	17 (21.3%)	21 (31.3%)
Interstitial pattern	10 (12.2%)	4 (5%)	7 (10.5%)
Pleural effusion	2 (2.4%)	1 (1.3%)	0 (0%)
Atelectasis	1 (1.2%)	1 (1.3%)	0 (0%)
Extension of abnormality in chest			
radiography PA projection			
<33%	32 (39.0%)	4 (5%)	4 (5.97%)
33-66%	38 (46.3%)	6 (7.5%)	9 (13.43%)
>66%	10 (12.2%)	9 (11.25%)	13 (19.45%)

*Plus-minus values are means (±SD). Rounding has been applied to percentages. Total may no be 100 because of rounding.

†Total number of patients varies among variables and follow up as mortality increases.

‡Some patients have more than one radiologic abnormality.

PA, posteroanterior.

Table 3. Laboratory data at admission and follow up*

Laboratory data – no. (%)	Admission (n=82) †	48 hours (n=79) †	7 days (n=51) †
Red cell count			
Haemoglobin, mean – gr/dl	13.3 ±1.6	12.7 ±1.6	12.5 ±1.5
≥ 10 gr/dl – no. (%)	78 (96.3%)	41 (93.2%)	43 (95.6%)
White cell count			
Mean (SD) – per mm ³	9.2 ±10.4	6.7 ±3.8	7.1 ±3.5
Distribution – no. (%)			
≥ 10000/mm ³	17 (21.3%)	5 (11.4%)	9 (20%)
≤4000/mm³	7 (8.8%)	10 (22.7%)	9 (20%)
Lymphocyte count			
Meidan (IQR) – per mm ³	868.9 (593.7-1205.5)	710.5 (491.5-	1112.0 (575.1-1519.6)
		1154.9)	
Distribution – no. (%)			
≥ 1000/mm³ – no. (%)	34 (42.5%)	15 (34.1%)	23 (51.1%)
Platelet count, mean – per mm³	199 ±87.2	235.7 ±139.4	282.3 ±141.6
Prothrombin time, mean - %	77.9 ±23.8		
Activated partial thrombopastin time, mean	24.6 ±9.8		
- seconds			
Fibrinogen, mean – gr/dl	5.6 ±1.0		

D dimer, median (IQR) - ng/ml	295 (201-437)	565 (303-772)	738 (273.5-2963)
Glucose, mean - mg/dl	120.2 ±36.7		
Urea, median (IQR) – mg/dl	43 (38-72)		
Serum creatinine, mean - mg/dl	1.7 ±6.1	2.1 ±7.1	0.9 ±0.6
Glomerular filtrate, mean – CKD-EPI	73.5 ±23.8	73.1 ±26.5	77.25 ±19.9
Sodium, mean – mmol/L	136.0 ±3.7		
Potasium, mean – mmol/L	3.9 ±0.7		
Calcium, mean – mg/dl	8.9 ±0.5		
Total bilirubin, mean – mg/dl	0.7 ±0.5		
Aspartate aminotransferase, mean - U/litre	53.1 ±34.3	53.7 ±35.4	71.4 ±46.2
Aspartate aminotransferase > 40 U/litre	42 (53.9%)	25 (61%)	30 (66.7%)
Alanine aminotransferase, mean - U/litre	41.68 (34.4)	43.4 (31.7)	77.3 (71)
Alanine aminotransferase > 40 U/litre	28 (35.4%)	16 (39.0%)	30 (66.7%)
Alkaline phosphatase, mean - U/litre	69.80 ±21.7		
Gamma-glutamyl transferase, mean – U/litre	93 ±58.0		
LDH, mean - UI/L	446.61 ±79.5		
CRP, mean - mg/dl	17.98 ±11.7	17.5 ±10.0	6.3 ±9.2
Ferritin, mean - ng/ml	885.69 ±500.5	1505.4 ±1194.6	1241.6 ±789.2
Proteins, mean - gr/dl	7.38 ±0.7		
Albumin, mean - gr/dl	3.30 ±0.3		
IL-6, median (IQR) - pg/ml	74.8 (49.4-120.0)	184.1 (75.3-592.6)	501.2 (103.7-2361.0)
Infection analysis			
Positive blood cultures	1 (1.3%)	0 (0%)	1 (10%)
Positive sputum cultures	3 (4.3%)	0 (0%)	2 (22.2%)
Positive pneumococcal urinary antigen	2 (2.5%)	0 (0%)	0 (0%)

^{*}Plus-minus values are means (±SD). Rounding has been applied to percentages. Total may no be 100 because of rounding.

[†]Total number of patients varies among variables and follow up as mortality increases.

Table 4. Oxygen supplementation and supportive ventilation on admission and follow up*

	Admission (n=82) †	48 hours (n=79) †	7 days (n=51) †
Respiratory frequency, mean – rate per minute	23.9 ±6.3	21.6 ±6	22.5 ±11.5
Oxygen saturation, mean	94 ±4.4	94 ±3.9	93.6 ±6.9
SpO2/FiO2 ratio, median (IQR)	428 (316.1-454.8)	271.4 (158.3- 361.5)	230.2 (118.8-346.4)
Oxygen supplementation and supportive ventilation – no. (%)			
Nasal cannula	2 (5.9%)	6 (9%)	4 (7.0%)
Face masks	22 (64.7%)	33 (49.3%)	16 (28.1%)
High oxygen supplementation device	9 (26.5%)	11 (16.4%)	6 (10.5%)
High flow nasal cannulas	0 (0%)	10 (14.9%)	16 (28.1%)
Non-invasive mechanical ventilation	0 (0%)	2 (3%)	3 (5.3%)
Invasive mechanical ventilation	1 (2.9%)	5 (7.5%)	12 (21.1%)

^{*}Plus-minus values are means (±SD). Rounding has been applied to percentages. Total may no be 100 because of rounding.

†Total number of patients varies among variables and follow up as mortality increases.

SpO2/FiO2 ratio: arterial oxygen saturation measured by pulse oximetry to fraction of inspired oxygen

Table 5. Secondary outcomes at 7-day follow up from tocilizumab administration.

Outcome – no. (%)	Patients
Vasopressor therapy	15 (19.7%)
Acute respiratory distress syndrome	45 (64.3%)
Respiratory failure	62 (84.9%)
Cardiac failure	1 (1.5%)
Septic shock	1 (1.6%)
Acute kidney injury	9 (13.9%)
Concomitant infection	1 (1.5%)

Table 6. Main outcome at 7-day follow up from tocilizumab administration.

Main outcomes - no. %	Patients
Discharge	34 (41.5%)
In-patient in conventional ward	9 (11.0%)
Intensive care unit	14 (17.1%)
Death	22 (26.8%)
Transferred	3 (3.7%)

Table 7. Comparison of risk factors by in-hospital mortality.

Characteristics	Alive (n=60)	Dead (n=22)	P-value
Demographics			
Age, mean (SD) - yr	53.3 (19.9)	75.2 (6.2)	<0.001
Sex – no (%)	36 (60.0)	16 (72.7)	0.289
Coexisting condition – no (%)			
Tobacco use			0.397
Active tabacco smoker	5 (8.3)	-	
Former tabacco smoker	19 (31.7)	9 (40.9)	
Never smoke	36 (60.0)	13 (59.1)	
Alcohol use			0.070
Active daily alcohol consumption	1 (1.7)	-	
Former daily alcohol consumption	-	2 (9.1)	

Never drink daily	59 (98.3)	20 (90.9)	
Barthel index at admission, median (IQR)	100 (100-100)	100 (100-100)	0.371
Dementia	1 (1.7)	-	1
Diabetes Mellitus	12 (20.0)	4 (18.2)	1
Immunosuppression	5 (8.3)	5 (22.7)	0.123
Solid tumor	3 (5.1)	6 (27.3)	0.012
Leukemia/Lymphoma	2 (3.3)	1 (4.6)	1
Hypertension	17 (28.3)	15 (68.2)	0.001
Chronic heart failure	1 (1.7)	4 (18.2)	0.017
Chronic lung disease	11 (18.6)	8 (36.4)	0.094
Chronic renal failure	4 (6.7)	7 (33.3)	0.005
Liver cirrhosis	1 (1.7)	-	1
Central nervous system disease	1 (1.7)	1 (4.6)	0.467
Obesity	14 (23.3)	3 (13.6)	0.539
Median (IQR), age-adjusted Charlson index at baseline - points	2 (1 – 3)	5 (3 – 6)	<0.001
Oxygenation previous to tocilizumab administration			
Oxygen saturation (pulse oximeter) at baseline, median (IQR)	95 (94 - 97.5)	93 (89 - 97)	0.061
FiO2 at baseline, median (IQR)	0.21 (0.21 - 0.28)	0.26 (0.21 - 0.50)	0.130
SpO2/FiO2 ratio at baseline, median (IQR)	440 (343-455)	393 (180-452)	0.134
High oxygen supplementation or ventilation at baseline* - no. (%)	-	1 (4.6%)	0.268
Oxigen saturation (pulse oximeter) at tocilizumab administration, median (IQR)	95 (93-97)	92 (89-94)	0.006
FiO2 previous to tocilizumab administration, median (IQR)	0.27 (0.21-0.40)	0.35 (0.21-1)	0.131
SpO2/FiO2 ratio previous to tocilizumab administration, median (IQR)	354 (228-438)	263 (95-423.8)	0.072
High oxygen supplementation or ventilation previous to tocilizumab administration*	3 (5%)	4 (18%)	0.79
Days from initial symptoms to tocilizumab administration, median (IQR)	9 (7 - 11)	7 (5 - 15)	0.372
Days from admission to tocilizumab administration, median (IQR)	2 (1 - 3)	3 (1 - 4)	0.064
Days from respiratory insufficiency to tocilizumab	0 (0 - 1)	1 (0 - 2)	0.055
	1	•	1

administration, median (IQR)			
Days from ARDS to tocilizumab administration, median (IQR)	0 (-1 - 0)	0 (0 - 1)	0.132

^{*}Plus-minus values are means (±SD). Rounding has been applied to percentages. Total may no be 100 because of rounding.

†Includes high flow oxygen delivery systems, high flow nasal cannula, non-invasive mechanical ventilation or invasive ventilation

ARDS: acute respiratory distress syndrome.







